home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

PTC Therapeutics, Inc. - Common Stock (NQ:PTCT)

68.23 -0.36 (-0.52%)

Streaming Delayed Price Updated: 4:00 PM EDT, Apr 24, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about PTC Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

Earnings Preview For PTC Therapeutics ↗

November 06, 2024

Via Benzinga

3 Top Stocks That Could Still Rocket Higher in 2024 ↗

October 04, 2024

Upcoming Food and Drug Administration decisions could push these stocks through the roof.

Via The Motley Fool

PTC Therapeutics Stock Earns RS Rating Upgrade To 83 ↗

August 19, 2024

The Relative Strength (RS) Rating for PTC Therapeutics stock climbed into a new percentile Monday, with a rise from 80 to 83.

Via Investor's Business Daily

PTCT Stock Earnings: PTC Therapeutics Misses EPS, Beats Revenue for Q2 2024 ↗

August 08, 2024

PTCT stock results show that PTC Therapeutics missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024.

Via InvestorPlace

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

July 10, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Recap: PTC Therapeutics Q4 Earnings ↗

February 29, 2024

Via Benzinga

Earnings Scheduled For February 29, 2024 ↗

February 29, 2024

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

Via Benzinga

Earnings Preview: PTC Therapeutics ↗

February 28, 2024

Via Benzinga

Analyst Expectations for PTC Therapeutics's Future ↗

November 20, 2023

Via Benzinga

PTC Therapeutics, Inc. (PTCT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

July 03, 2024

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session ↗

June 28, 2024

Via Benzinga

PTC Therapeutics Tumbles After European Regulators Reject Its Drug — Again ↗

June 28, 2024

The company plans to ask for another re-examination for its drug in Europe.

Via Investor's Business Daily

Asana, Clover Health Investments, Hertz Global And Other Big Stocks Moving Higher On Friday ↗

June 21, 2024

Via Benzinga

PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder ↗

June 20, 2024

PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on PTC518 for Huntington's disease. The FDA has lifted the partial clinical hold on the program.

Via Benzinga

The 3 Most Undervalued Biotech Stocks to Buy in June 2024 ↗

June 04, 2024

https://seekingalpha.com/news/4111624-goldman-sachs-raises-obesity-drug-market-estimate

Via InvestorPlace

Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

May 20, 2024

Via Benzinga

European Commission Requests Reevaluation Of Opinion On PTC Therapeutics' Duchenne Dystrophy Drug; Pauses Annual Guidance ↗

May 20, 2024

PTC Therapeutics announced that the European Commission has asked the CHMP to re-evaluate its negative opinion on the renewal of Translarna's conditional marketing authorization, keeping it available...

Via Benzinga

Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday ↗

May 20, 2024

Via Benzinga

PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day' ↗

May 20, 2024

The EC is asking its committee to reexamine its decision on Translarna.

Via Investor's Business Daily

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 20, 2024

Via Benzinga

PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 ↗

May 01, 2024

PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72.

Via Investor's Business Daily

PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024 ↗

April 25, 2024

PTCT stock results show that PTC Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

Via InvestorPlace

Cooper Companies Reports Upbeat Results, Joins Dell, NetApp, Tidewater And Other Big Stocks Moving Higher On Friday ↗

March 01, 2024

U.S. stocks were higher, with the Nasdaq Composite gaining around 0.5% on Friday.

Via Benzinga

Topics Stocks

1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock? ↗

February 11, 2024

Bad news for one player does not always equal good news for another.

Via The Motley Fool

PTC Therapeutics Flashes A Bearish Sign After European Officials Reject DMD Drug ↗

January 26, 2024

European regulators will likely force PTC Therapeutics to pull its drug, Translarna, from the market.

Via Investor's Business Daily

PTC Therapeutics To Withdraw Its Conditionally Approved Rare Muscle Disorder Disorder Drug In Europe ↗

January 26, 2024

CHMP issues negative opinion on PTC Therapeutics' Translarna for Duchenne Muscular Dystrophy. CEO expresses disappointment.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

January 26, 2024

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

January 25, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

October 27, 2023

Via Benzinga

Why Is Gene Therapy Player PTC Therapeutics Stock Plunging Today? ↗

October 27, 2023

In its Q3 earnings release, PTC Therapeutics Inc (NASDAQ: PTCT) reported a

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com